Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
Andreana Foresta, Luisa Ojeda‐Fernández, Giulia Macaluso, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 4, pp. e115-e126
Open Access | Times Cited: 9

Showing 9 citing articles:

SGLT2 Inhibitors in COVID-19: Umbrella Review, Meta-Analysis, and Bayesian Sensitivity Assessment
Vinay Suresh, Muhammad Aaqib Shamim, Victor Ghosh, et al.
Diseases (2025) Vol. 13, Iss. 3, pp. 67-67
Open Access
The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, et al.
Therapeutic Innovation & Regulatory Science (2024) Vol. 58, Iss. 4, pp. 773-787
Closed Access | Times Cited: 3
Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
Carmen Tisch, Eleni Xourgia, Aristomenis K. Exadaktylos, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 660-675
Open Access | Times Cited: 2
Combination of spironolactone and DPP-4 inhibitors for treatment of SARS-CoV-2 infection: a literature review
Kamyar Asadipooya, Artin Asadipooya, Reuben Adatorwovor
Archives of Virology (2024) Vol. 169, Iss. 6
Closed Access | Times Cited: 2
Immunomodulatory activity of dipeptidyl peptidase‐4 inhibitors in immune‐related diseases
Marija Drakul, Miodrag Čolić
European Journal of Immunology (2023) Vol. 53, Iss. 12
Open Access | Times Cited: 3
The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan
Health Science Reports (2023) Vol. 6, Iss. 9
Open Access | Times Cited: 2
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?
Medine Cumhur Cüre, Erkan Cüre
Current Pharmaceutical Design (2024) Vol. 30, Iss. 15, pp. 1149-1156
Closed Access
SGLT2 Inhibitors in COVID-19: Umbrella Review, Meta-analysis, and Bayesian Sensitivity Assessment
Vinay Suresh, Muhammad Aaqib Shamim, Victor Ghosh, et al.
Research Square (Research Square) (2024)
Open Access
Authors’ reply to correspondence to “Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium. Ann Endocrinol (Paris). 2023 Aug 31:S0003-4266(23)00685-6. doi: 10.1016/j.ando.2023.08.002”
Laura Orioli, Thomas Servais, Laurent Crenier, et al.
Annales d Endocrinologie (2023) Vol. 84, Iss. 6, pp. 790-791
Closed Access
Page 1

Scroll to top